Kadmon Holdings Inc (KDMN) Director Eugene Bauer Purchases 5,000 Shares
Kadmon Holdings Inc (NASDAQ:KDMN) Director Eugene Bauer purchased 5,000 shares of the stock in a transaction on Tuesday, August 8th. The shares were purchased at an average cost of $2.36 per share, with a total value of $11,800.00. Following the transaction, the director now owns 1,716 shares of the company’s stock, valued at approximately $4,049.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Kadmon Holdings Inc (NASDAQ KDMN) opened at 2.48 on Wednesday. The stock’s market cap is $128.58 million. Kadmon Holdings Inc has a 12 month low of $2.19 and a 12 month high of $10.48. The stock has a 50 day moving average price of $3.17 and a 200 day moving average price of $3.26.
Kadmon Holdings (NASDAQ:KDMN) last posted its earnings results on Thursday, August 3rd. The company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. The business had revenue of $3 million for the quarter, compared to analyst estimates of $3.46 million. The company’s quarterly revenue was down 53.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($4.40) earnings per share. Equities analysts anticipate that Kadmon Holdings Inc will post ($1.62) EPS for the current fiscal year.
A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Kadmon Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Kadmon Holdings in a research report on Monday, June 26th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $7.00 target price on shares of Kadmon Holdings in a research report on Friday, July 14th. Finally, ValuEngine downgraded Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $9.93.
Several large investors have recently modified their holdings of KDMN. Perceptive Advisors LLC increased its stake in shares of Kadmon Holdings by 134.7% in the first quarter. Perceptive Advisors LLC now owns 5,185,847 shares of the company’s stock valued at $18,772,000 after buying an additional 2,976,190 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in shares of Kadmon Holdings during the fourth quarter valued at about $2,696,000. JPMorgan Chase & Co. increased its stake in shares of Kadmon Holdings by 11,654.8% in the first quarter. JPMorgan Chase & Co. now owns 228,866 shares of the company’s stock valued at $829,000 after buying an additional 226,919 shares in the last quarter. AE Wealth Management LLC acquired a new stake in shares of Kadmon Holdings during the first quarter valued at about $391,000. Finally, Nationwide Fund Advisors acquired a new stake in shares of Kadmon Holdings during the first quarter valued at about $192,000.
About Kadmon Holdings
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.